334 related articles for article (PubMed ID: 34020790)
1. Overcoming the challenges of tissue delivery for oligonucleotide therapeutics.
Gökirmak T; Nikan M; Wiechmann S; Prakash TP; Tanowitz M; Seth PP
Trends Pharmacol Sci; 2021 Jul; 42(7):588-604. PubMed ID: 34020790
[TBL] [Abstract][Full Text] [Related]
2. Liver as a target for oligonucleotide therapeutics.
Sehgal A; Vaishnaw A; Fitzgerald K
J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
[TBL] [Abstract][Full Text] [Related]
3. The chemistry and biology of oligonucleotide conjugates.
Juliano RL; Ming X; Nakagawa O
Acc Chem Res; 2012 Jul; 45(7):1067-76. PubMed ID: 22353142
[TBL] [Abstract][Full Text] [Related]
4. RNA therapeutics for metabolic disorders.
Vu TD; Lin SC; Wu CC; Chu DT
Prog Mol Biol Transl Sci; 2024; 203():181-196. PubMed ID: 38359998
[TBL] [Abstract][Full Text] [Related]
5. Delivery of RNA Therapeutics: The Great Endosomal Escape!
Dowdy SF; Setten RL; Cui XS; Jadhav SG
Nucleic Acid Ther; 2022 Oct; 32(5):361-368. PubMed ID: 35612432
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
7. RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions.
MacLeod AR; Crooke ST
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S43-S59. PubMed ID: 28921648
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases.
Ossipov DA
Expert Opin Drug Deliv; 2019 Jun; 16(6):621-637. PubMed ID: 31072142
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics.
Finicle BT; Eckenstein KH; Revenko AS; Anderson BA; Wan WB; McCracken AN; Gil D; Fruman DA; Hanessian S; Seth PP; Edinger AL
Nucleic Acids Res; 2023 Feb; 51(4):1583-1599. PubMed ID: 36727438
[TBL] [Abstract][Full Text] [Related]
10. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.
Crooke RM; Graham MJ
Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993
[TBL] [Abstract][Full Text] [Related]
11. Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines.
Michel S; Schirduan K; Shen Y; Klar R; Tost J; Jaschinski F
Mol Diagn Ther; 2021 Jan; 25(1):77-85. PubMed ID: 33314011
[TBL] [Abstract][Full Text] [Related]
12. Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.
Miller CM; Tanowitz M; Donner AJ; Prakash TP; Swayze EE; Harris EN; Seth PP
Nucleic Acid Ther; 2018 Jun; 28(3):119-127. PubMed ID: 29425080
[TBL] [Abstract][Full Text] [Related]
13. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
[TBL] [Abstract][Full Text] [Related]
14. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.
Ming X
Expert Opin Drug Deliv; 2011 Apr; 8(4):435-49. PubMed ID: 21381985
[TBL] [Abstract][Full Text] [Related]
15. RNA-Targeted Therapeutics.
Crooke ST; Witztum JL; Bennett CF; Baker BF
Cell Metab; 2018 Apr; 27(4):714-739. PubMed ID: 29617640
[TBL] [Abstract][Full Text] [Related]
16. Re-Engineering RNA Molecules into Therapeutic Agents.
Egli M; Manoharan M
Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
[TBL] [Abstract][Full Text] [Related]
17. Advances in therapeutic bacterial antisense biotechnology.
Hegarty JP; Stewart DB
Appl Microbiol Biotechnol; 2018 Feb; 102(3):1055-1065. PubMed ID: 29209794
[TBL] [Abstract][Full Text] [Related]
18. Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
Hammond SM; Aartsma-Rus A; Alves S; Borgos SE; Buijsen RAM; Collin RWJ; Covello G; Denti MA; Desviat LR; Echevarría L; Foged C; Gaina G; Garanto A; Goyenvalle AT; Guzowska M; Holodnuka I; Jones DR; Krause S; Lehto T; Montolio M; Van Roon-Mom W; Arechavala-Gomeza V
EMBO Mol Med; 2021 Apr; 13(4):e13243. PubMed ID: 33821570
[TBL] [Abstract][Full Text] [Related]
19. RNA Therapeutics: How Far Have We Gone?
Coutinho MF; Matos L; Santos JI; Alves S
Adv Exp Med Biol; 2019; 1157():133-177. PubMed ID: 31342441
[TBL] [Abstract][Full Text] [Related]
20. Tissue-Specific Delivery of Oligonucleotides.
Xia X; Pollock N; Zhou J; Rossi J
Methods Mol Biol; 2019; 2036():17-50. PubMed ID: 31410789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
